0      0

AONN+ Annual 2020


SAT02 - General Session 7 | Biosimilars


Nov 7, 2020 8:45am ‐ Nov 7, 2020 9:45am

Description

This session will discuss biosimilars, their mechanism of action, and how to incorporate their use in patient treatments. Focus will be drawn on cost benefits and challenges encountered related to approval of biosimilars and how creation of more biosimilars will affect the pharmaceutical landscape.

Learning Objectives:
  • Define what is considered a biosimilar.
  • Discuss biosimilars’ mechanism of action.
  • Increase awareness on when incorporating biosimilars into treatments plans is beneficial.
  • Discuss the process of obtaining coverage and funding/coverage for biosimilars.

Speaker(s):

  • Ali McBride, PharmD, MS, Clinical Coordinator, The University of Arizona Cancer Center
  • Angie Santiago, CRCS, Lead Financial Advocate, Sidney Kimmel Cancer Center/Jefferson Health

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content